{"news_desk": "Business", "print_page": "1", "subsection_name": null, "section_name": "Business Day", "byline": {"original": "By KATIE THOMAS", "person": [{"firstname": "Katie", "rank": 1, "lastname": "THOMAS", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "780", "keywords": [{"rank": "1", "value": "Mylan Inc", "is_major": "Y", "name": "organizations"}, {"rank": "2", "value": "Medical Devices", "is_major": "N", "name": "subject"}, {"rank": "3", "value": "Justice Department", "is_major": "N", "name": "organizations"}, {"rank": "4", "value": "Epinephrine (Drug)", "is_major": "Y", "name": "subject"}, {"rank": "5", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "name": "subject"}, {"rank": "7", "value": "Allergies", "is_major": "Y", "name": "subject"}, {"rank": "8", "value": "Generic Brands and Products", "is_major": "Y", "name": "subject"}, {"rank": "9", "value": "Medicaid", "is_major": "N", "name": "subject"}], "lead_paragraph": "The government said Mylan had wrongly claimed EpiPen as a generic, leading Medicare and Medicaid to overpay for it. The company said the settlement included no admission of wrongdoing.", "pub_date": "2016-10-08T04:00:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "The government said Mylan had wrongly claimed EpiPen as a generic, leading Medicare and Medicaid to overpay for it. The company said the settlement included no admission of wrongdoing....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/09/16/business/08mylan1/08mylan1-thumbWide-v3.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/09/16/business/08mylan1/08mylan1-thumbWide-v3.jpg"}, {"height": 456, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "456", "xlarge": "images/2016/09/16/business/08mylan1/08mylan1-articleLarge-v3.jpg"}, "type": "image", "width": 600, "url": "images/2016/09/16/business/08mylan1/08mylan1-articleLarge-v3.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/09/16/business/08mylan1/16EPIPENLOBBY2-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/09/16/business/08mylan1/16EPIPENLOBBY2-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/10/08/business/epipen-mylan-justice-department-settlement.html", "slideshow_credits": null, "blog": [], "_id": "57f8125495d0e021d798abfa", "headline": {"main": "Mylan to Settle EpiPen Overpricing Case for $465 Million", "print_headline": "Mylan to Pay $465 Million in EpiPen Overpricing Case"}}